<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Recapitulating Clinical Metastatic Events in Preclinical Mouse Models

diagram of the multistep process of tumor metastasis

diagram of the multistep process of tumor metastasisExplore the preclinical mouse models that best recapitulate the progression of the clinical metastatic process.

Investigating Metastatic Cancer

Metastatic cancer has devastating consequences for patients and causes more than 90% of cancer-related deaths. The formation of a metastasis is a highly inefficient process that results from a series of events permitting cancer cells to:

  • Migrate from the primary tumor site.

  • Survive in the lymphatic system or blood vessels.

  • Extravasate.

  • Grow at a distant site(s) to form secondary tumors.

The propensity of a primary tumor to become metastatic is highly complex, and the details are still being deciphered. However, it is thought to be highly influenced by genomic alterations (genetic and epigenetic) within cancer cells and contributions from the tumor microenvironment.

Preclinical Mouse Models of Metastasis

Preclinical oncology mouse models play an important role in advancing our knowledge of the complex interactions and stages of the metastatic process. Improved models are helping researchers gain a better understanding of the underlying biological processes, as well as develop novel therapeutics to block metastasis or more efficiently treat already established metastases.

There are several approaches used to generate metastases in preclinical mouse models, and various considerations must be taken into account when selecting a metastasis model. These include the mouse strain (including its immune status), transplantation location (e.g. subcutaneous/ectopic, orthotopic, i.v.), and origin and type of transplanted cells (e.g. primary or immortalized human/mouse cancer cell lines, resected patient tumors).

Cell line derived syngeneic and xenograft models are commonly and successfully used to model the metastatic processes associated with various types of cancer. Examples include:

  • Syngeneic: melanoma using the B16-F10 cell line and breast cancer using the 4T1 cell line.

  • Xenograft: breast cancer using the MDA-MB-231 cell line.

The syngeneic models are in the context of a fully competent mouse immune system, whereas xenografts are in immunodeficient environment.

Two models that offer distinct advantages in metastasis modeling are genetically engineered mouse models and patient-derived orthotopic xenografts.

Studying Metastasis with Genetically Engineered Mouse Models (GEMMs)

Several key characteristics of metastasis were discovered using GEMMs, including that metastasis can occur early during tumorigenesis. It had been previously thought that metastasis only occurred late in the process.

A variety of GEMMs of different indications are available for modeling the metastatic process. These models display de novo tumor progression and metastasis formation in an immune-competent tumor microenvironment. This makes GEMMs well-suited models for studying the functional roles of various components of cellular signaling pathways, the tumor microenvironment, and immune response.

Through the development of de novo tumors, GEMMs enable modeling of the tumor’s cell-autonomous and stromal influences on all stages of the metastatic cascade. For this reason, models that allow conditional activation of oncogenes and/or inactivation of tumor suppressor genes in somatic cells recapitulate many of the key characteristics of human disease.

Examples of these models are detailed below for different cancer indications.

Breast Cancer

MMTV-PyMT is the most commonly used mouse model for the study of mammary tumor progression and metastasis. MMTV-PyMT transgenic mice express the Polyoma Virus middle T antigen under the transcriptional control of the mouse mammary tumor virus promoter/enhancer. This model shares many aspects of breast cancer progression seen in humans, characterized by multistage progression from hyperplasia to late carcinoma followed by metastatic lesions in the lymph nodes and in the lungs.

Prostate Cancer

Several strategies have been used to generate prostate cancer mouse models. One of the most popular models is the Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model for prostatic adenocarcinomas. The TRAMP model is based on SV40 T antigen oncoprotein expression under probasin. Distant metastasis is observed in lymph nodes and lung and occasionally in bone, kidney, and adrenal glands.

Lung Cancer

The most frequently-used mouse model for inducible lung cancer development is the LSL-KRASG12D model. This model harbors an activated form of KRAS, regulated by a LoxP-Stop-LoxP (LSL) transcriptional cassette.

Cre induction by inhalation of recombinant adenovirus leads to the deletion of the LSL transcriptional stop cassette allowing KRASG12D expression and the formation of lung adenocarcinomas. LSL-KRASG12D;Trp53flox/flox composite mice then develop metastases to lymph nodes, pleura, kidney, heart, adrenal glands, and liver with high frequency.

Pancreatic Cancer

Similar to lung adenocarcinoma models, many models for pancreatic ductal adenocarcinoma (PDAC) rely on LSL-KRASG12D mice. GEMMs that harbor KrasG12D, Trp53R172H and Pdx-1Cre (known as KPC) recapitulate the pathological characteristics of human pancreatic cancer with metastasis to multiple organs including the liver, lymph nodes, lung, diaphragm, and adrenal glands.

Colon Cancer

Despite the wide number of colon cancer GEMM developed, few show metastases with considerable efficiency. As an example LSL-KRASG12V; APC flox/flox mice, when administrated with Cre adenovirus in the colon, induces the loss of APC and activation of oncogenic KRASG12V leading to sporadic tumor development followed by liver metastasis.

Patient-Derived Orthotopic Xenografts (PDOX): Better Mimicking Patient Tumors

Patient-derived xenografts (PDXs) can be transplanted into immunocompromised recipient mice either subcutaneously or orthotopically. They are most commonly established subcutaneously because transplantation is less technically demanding and allows for efficient monitoring of tumor growth.

Advantages of Orthotopic Xenograft Models

However, a wealth of experience has demonstrated that the majority of subcutaneous PDX models do not metastasize. In contrast, patient-derived orthotopic xenograft (PDOX) models, which entail the orthotopic implantation of intact tumor tissue, can lead to metastasis. This more closely resembles the true propensity of human tumors to metastasize and might better recapitulate their underlying metastatic processes. PDOX models have been successfully established using various tumor types, including pancreatic, lung, mammary, and colon.

Orthotopically-implanted tumors have also been shown to be superior for mimicking drug response, tumor growth patterns, and metastatic features (also see here) of corresponding patient tumors, which is likely due to the important influences imparted by the local stroma.

Disadvantages of Orthotopic Xenograft Models

Orthotopic transplantation, however, can be time consuming and more technically challenging. It also often requires imaging (e.g. ultrasound, CT scan) or exploratory laparotomies to confirm the presence of internal tumors. Sometimes, there is a long latency, so resection of the primary tumor might be required to allow metastases to develop.


Metastatic disease is a devastating consequence of cancer for many patients. Preclinical mouse models that better recapitulate the full spectrum of the metastatic process are more likely to produce translatable research that improves their clinical prognosis.

Careful consideration should be taken when selecting your metastatic model. GEMMs offer important benefits for modeling metastasis in immunocompetent animals, while orthotopic PDX models demonstrate higher fidelity of the metastatic process.

Related Posts